ACoP14

Welcome to ACoP

 

ACoP14 Scientific Program (pre-final)

 

Saturday, November 4, 2023

Start

End

Event

Vendors

7:00 AM

8:00 AM

Registration & Coffee Service -Workshop Attendees

8:00 AM

5:00 PM

Pre-Meeting Workshop ( 1 day) - Model-Based Meta-Analysis (MBMA): Concepts, Methodologies, and Hands-on Workshop

Certara

8:00 AM

5:00 PM

Pre-Meeting Workshop (1 day) - Finch Studio NONMEM Workbench with Case Studies in Target-Mediated Drug Disposition

Enhanced Pharmacodynamics

8:00 AM

5:00 PM

Pre-Meeting Workshop (1 day) - Applying PBBM/PBPK Modeling to Predict Absorption-Related Drug-Drug Interactions: Approaches, Special Considerations, and link toward population PK"

Simulations Plus

8:00 AM

5:00 PM

Pre-Meeting Workshop (2 day) - Scientific Modeling Augmented by Machine-Learning with DeepPumasTM

Pumas AI

8:00 AM

5:00 PM

Pre-Meeting Workshop - Introduction and use of jinko:  the first end-to-end in silico trial platform to translate biomedical knowledge into actionable QSP models

Novadiscovery

8:00 AM

5:00 PM

Pre-Meeting Workshop (1 day) - Reporting Pharmacometrics Analyses Introduction to Quarto

Gilead Sciences

8:00 AM

5:00 PM

Pre-Meeting Workshop (1 day) - Hands-On Tutorial: Introduction to Immuno-Oncology (IO) Quantitative Systems Pharmacology (QSP) Modeling Using the Open Source Julia Progamming Language

Metrum Research Group

12:00 PM

1:00 PM

Lunch for pre ACoP14 Workshops Attendees

3:00 PM

3:30 PM

Coffee Break for pre ACoP14 Workshops Attendees

Sunday, November 5, 2003

Start

End

Event

Vendors

7:00 AM

8:00 AM

Registration & Coffee Service - Workshop Attendees

8:00 AM

5:00 PM

Pre Meeting Workshop (1 Day) Simcyp Designer PBPK-QSP Focused Workshop

Certara

8:00 AM

12:00 PM

Pre Meeting Workshop (1/2 day) - Global Sensitivity Analysis with SimBiology

Mathworks

8:00 AM

5:00 PM

Pre Meeting Workshop (1 Day) - New and Advanced Methods of NONMEM7 

ICON

8:00 AM

5:00 PM

Pre Meeting Workshop (1 Day) - Modeling Delays in Pharmacokinetics and Pharmacodynamics using NONMEM.

ISoP MCS SIG

8:00 AM

5:00 PM

Pre Meeting Workshop (2 Day) Scientific Modeling Augmented by Machine-Learning with Deep PumasTM

Pumas AI

8:00 AM

5:00 PM

Pre Meeting Workshop (1 Day) Effective Simulation with mrgsolve for Model-Informed Drug Development

Metrum Research Group

8:00 AM

5:00 PM

Pre Meeting Workshop (1 Day) An introduction to probabilistic decisions support in drug development

Pharmetheus

12:00 PM

1:00 PM

Lunch for pre ACoP14 Workshops Attendees

12:00 PM

7:30 PM

ACoP14 Conference Registration

1:00 PM

5:00 PM

Pre Meeting Workshop (1/2 Day)Practical application of MID3 to inform Early Drug Discovery Decisions using Applied BioMath Assess

Applied BioMath LLC

3:00 PM

3:30 PM 

Coffee Break for pre ACoP14 Workshops Attendees

5:00 PM

5:30 PM

ISoP Awards & Fellows Reception (by invitation only)

5:30 PM

7:30 PM

ACoP14 Opening Session: Welcome/Conference Highlights

Sihem Bihorel - Merck & Co, ACoP14 Conference Chair

Presentation of ISoP Awards & Induction of Fellows

Navin Goyal - Janssen, ISoP Awards Committee Chair

Lewis B. Sheiner Award Lecture

TBD

7:30 PM

10:00 PM

Opening Reception

Monday, November 6, 2023

Start

End

Event

Chairs & Speakers & Panelists

7:00 AM

9:00 AM

Exhibits/Posters/Coffee Service

9:00 AM

10:00 AM

General Session: President's Address

President: Cynthia J. Musante - Pfizer

President-Elect: Vijay Ivaturi - Pumas AI

10:00 AM

11:00 AM

State-of-the-Art Lecture: Utility of multi-scale modeling of multi-organ systems in understanding and decision-making in drug development

Dr. Melissa Hallow - University of Georgia

11:15 AM

1:00 PM

Innovation & Diversity: Redefining Pharmacometrics

Chairs: Sihem Bihorel - Merck & Co, Eric Sobie - Ichan School of Medicine at Mount Sinai, Florencio Serrano Castillo - Amgen

Strengthening Pharmacometrics in Africa: a long-term commitment

Goonaseelan (Colin) Pillai - Pharmacometrics Africa NPC

DEI in digital health & analytics: the promise and the pitfalls

Saroja Ramanujan - Generate Biomedicines

Leveraging Diversity to further Innovation: Developing Drugs for a Representative US population

Lanre Okusanya - FDA

11:15 AM

1:00 PM

The present and future of MIDD: focusing on drug development and human health

Chairs: Emmanuel Chigutsa - Eli Lilly & Ye Xiong - FDA

The Use of MIDD Approaches to Enhance New Drug Development and Patient Care

Jiang Liu - FDA

Novel applications of MIDD: current and next steps

Amitava Mitra - Kura Oncology

Diverse and innovative applications of pharmacometrics in global health

Rada Savic - UCSF

Moving Boundaries: Towards Virtual Twin Patients in Clinical Trials and Precision Medicine for CNS Disorders.

Hugo Geerts - Certara

11:15 AM

1:00 PM

Redefining Pharmacometrics: Is machine learning need-to-have or nice-to-have?

Chairs: Lyndsey Meyer - Pfizer & Peter Bloomingdale - Boehringer Ingelheim

Generative Adversarial Networks for Modeling the Race/Ethnicity, Age, and Disease Dependence of Physiological Determinants of Dosing

Murali Ramanathan - SUNY at Buffalo

Are ML methods superior to Cox proportional-hazards model for survival analysis? The answer may surprise you!

Antari Khot - Takeda

Advantages of Data-Centric Large Language Models for the field of Bio-NLP

Abhishek Jha - Elucidata

An Artificial Intelligence Framework for Optimal Drug Design

Grace Ramey - UCSF

1:00 PM

2:30 PM

Exhibits/Posters

1:00 PM

2:30 PM

Lunch

1:00 PM

2:30 PM

Trainee Lunch - A Speed Mentoring Event for Trainees to Talk with Professionals from all different walks of life, disciplines, and experiences

Vincent Lowe & Jessica Barry, ISoP Trainee Community Hosts

2:30 PM

4:00 PM

Model-based optimization for (CAR-T) Cell Therapies - The current state of affairs and a way forward

Chairs: Anna Mc Laughlin - Pharmetheus AB & Cassian Yee - Univ of TX, MD Anderson Cancer Center

Pharmacodynamic Analysis and QSP modeling for Phase-1 trial of TAK-102: a GPC3 Targeted CAR-T cell armored with IL-7 and CCL19 in Cancer patients

Aman Singh - Takeda Pharmaceuticals

Can we apply AI for identification of optimal candidates for cellular therapy?

Loretta Nastoupil - University of TX, MD Anderson Cancer Center

Mechanistic modeling of the lymphodepleting regimen to improve allogeneic CAR-T cell kinetics.

Thibaud Derippe - AstraZeneca

Clinical Pharmacology Considerations for the Development of CAR-T cell products

Xiaofei Wang - FDA

Unlocking the potential of pharmacometrics in cell therapy development and application

Panel Discussion – Session’s speakers and chairs

2:30 PM

4:00 PM

Emerging use of non-traditional healthcare data sources to enhance the impact of MIDD in advancing drug development program

Chairs: Malidi Ahamadi - Sanofi & Flora Musuamba Tshinanu - EMA

Deconvoluting data sharing and integration beyond Randomized controlled trials

Klaus Romero - C-Path Institute

Data, Code and Model Coexistence in a Digital Research Environment (DRE): Accelerating MIDD via Diverse Data in a Secure, Regulated Environment

Jeffrey Barrett - Aridhia Digital Research Environment

AI and Cloud: Power of Modern Trial Infrastructure for Accelerated Drug Development

Olga Kubassova - Image Analysis Group

Regulatory perspective on non-traditional healthcare data sources

Flora Musuamba Tshinanu - EMA

2:30 PM

4:00 PM

Prediction of target-site drug exposure and receptor occupancy in oncology

Chairs: David Busse - Boehringer Ingelheim & Eric Jodie - Metrum RG

Minimal Quantitative Systems Pharmacology (QSP) approach for early estimation of target engagement for different modalities

Lourdes Curcull-Sanchez - GSK

The Use of Minimal Physiology-based Pharmacokinetics Models and Biodistribution Studies to Predict Tumor Penetration and Receptor Occupancy

Robin Michelet - qPharmetra

Whole-body PBK model application to predict target occupancy in tumors from imaging data

Wilbert de Witte - esqLABS GmbH

To be selected from Abstracts

TBD

4:00 PM

5:00 PM

Exhibits/Posters/Coffee Service

5:00 PM

6:30 PM

ISoP Trainee Communication Challenge 

Hosts: Vincent Lowe & Jessica Barry, ISoP Trainee Community

Mentor: Stacey Tannenbaum – Metrum RG

7:00 PM

11:00 PM

Social Dinner Event

Janelle Lennie - GSK & Sonoko Kawakatsu - Metrum RG (ACoP14 Social Committee Co-Chairs)

Tuesday, November 7, 2023

Start

End

Event

Chairs & Speakers & Panelists

7:30 AM

9:30 AM

Exhibits/Posters/Coffee Service

9:30 AM

10:45 AM

Keynote Speaker: Enabling Patient-Centric Drug Development: an opportunity for clinical pharmacology and pharmacometrics to leverage innovation and advance diversity and inclusion

Dr. Lisa Benincosa - Allucent

11:00 AM

12:30 PM

Quality & Trainee Awards

12:30 PM

2:00 PM

Exhibits/Posters

12:30 PM

2:00 PM

Lunch

12:30 PM

2:00 PM

SIG Lunch - QSP

12:30 PM

2:00 PM

SIG Lunch - SxP  

2:00 PM

3:30 PM

Integration of PMx approaches to model-informed decision making: Across SIG Perspectives

Chairs: Luke Fostvedt - pfizer (SxP SIG), Iannis Androulakis - Univ Rutgers (QSP SIG), Sean Avedissian - UNMC (Clin PMx SIG), Tongli Zhang - Univ Cincinati (MCS SIG).

Panelists: Phyllis Chan - Genentech (SxP SIG), Meghan McCabe Pryor - Janssen (QSP SIG), Ada Zhuang - BMS (Clin PMx SIG), Helen Moore - Univ Florifda (MCS SIG)

Integrating statistics and PMx techniques for model-informed decision making in SLE - SxP SIG

Jonathan French - Metrum RG, Kosalaram Goteti - EMD Serono

The need for virtual patients and how QSP can provide an integrative framework - QSP SIG

Anna Kondic, Bristol Myers Squibb

Integration of a Bayesian software for model-informed Vancomycin precision dosing in an academic medical center - Clin PMx SIG

Sean N Avedissian -UNMC (College of Pharmacy), Jeremy Tigh - UNMC

Needs for mathematical and computational methods in model-informed drug development - MCS SIG

Jeroen Elassaiss-Schaap - PD-value B.V.

2:00 PM

3:30 PM

Many Roads Traveled: Diverse Journeys in Pharmacometrics

Chairs: Michelle Johnson - Metrum RG & Songmao (Ben) Zheng - Adagene

Speakers/Panelists: Emmanuel Chigusta- Eli Lilly, Sara Quinney - Indiana University, Mark Dresser- Gilead Sciences, Angela James – MacroGenics, Jeff Kearns - Novartis

2:00 PM

3:30 PM

PBPK Model for Therapeutic Protein-Drug Interactions (TP-DIs): Present and Future

Chairs: Weirong Wang - Janssen & Chunze Li - Genentech

Clinical pharmacology considerations for TP-DI

Xiling Jiang - FDA

Application of PBPK model in predicting TP-DI with cytokine modulators

Xian Pan - Certara

PBPK model of ADCs and its impact on clinical DDI strategy and label negotiation

Chunze Li - Genentech

Pharmacodynamics (PD)-mediated drug-drug interactions (DDI) for anti-FcRn agents and Fc-based therapeutic proteins

Jia Zhou - Janssen

3:30 PM

4:30 PM

Exhibits/Posters/Coffee Service

5:00 PM

6:00 PM

Universities' Receptions 

Tao Niu - Vertex Pharmaceuticals - ACoP14 Alumni Committee Chair

6:00 PM

7:30 PM

President's Reception (by invitation only)

Wednesday, November 8, 2023

Start

End

Event

Chairs & Speakers & Panelists

7:00 AM

9:00 AM

Exhibits/Posters/Coffee Service

9:00 AM

10:30 AM

Innovative Clinical Study Decision Making Using Quantitative Systems Pharmacology/Toxicology: An MIDD Tool

Chiars: Holly Kimko - AstraZeneca & Lourdes Cucurull-Sanchez - GSK

Combining Microphysiological System with AI and in silico Applications in Drug Development

Carmen Pin - AstraZeneca

Predicting Disease Activity Scores in Inflammatory Bowel Disease by Connecting Simulated Tissue Biomarkers of a Virtual Population to Clinical Biomarkers and Outcomes Using a Novel Algorithm

Douglas Chung - Certara

Mechanistic models defining and supporting optimal doses

Antoine Soubret - Roche

Engineering to Balance Efficacy and Safety – Optimizing Trimer Formation in T Cell Redirecting Bispecific Antibodies

Shalla Hanson - Janssen 

9:00 AM

11:00 AM

Roller Coaster 1

Chairs: Eric Sobie - Chairs: Anna Sher – GSK & Piet van der Graaf - Certara

Pharmacometabolomic-guided precision dosing in clinical care of hematopoietic cell transplantation (HCT) recipients

Jeannine S. McCune - City of Hope

Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers: a Regulatory Perspective

David Strauss - FDA 

Metabolomics-based Clinical Translation of Drug-induced Nephrotoxicity and Reno-protection With a Multiscale Modeling Approach

Sihem Bihorel - Merck & Co

Mapping lesion-specific response and progression dynamics in metastatic colorectal cancer

Jiawei Zhou - Pfizer

UDE Know It If UDE Saw It: Leveraging Deep Machine Learning for QSP Model Development and Evaluation

Ahmed Elmokadem - Metrum Research Group

Exploration of multiple AI search algorithms for nonlinear mixed effects model identification

Robert Bies - SUNY at Buffalo

9:00 AM

11:00 AM

Roller Coaster 2

Chairs: Kayla (Yi Ting) Lien – Genentech & Eric Sobie – Icahn School of Medicine at Mount Sinai

QSP Modelers: Take Your Data Seriously, Not Literally!

Christina Friedrich - Rosa & Co

Modelling pharmacometrics data with Neural ODEs including inter-individual variability

Dominic Braem - University of Basel

Open Problems in Generating Virtual Populations

Richard Allen - Pfizer

Prediction of human dose for gene replacement therapies

Sergey Aksenov - Arvinas

A Novel Bayesian Statistical Approach for Estimating Tumor Dynamics from Published Progression Free Survival Studies In the Presence of Response and Nontarget Progression

Arya Pourzanjani - Amgen

Minding your P’s and Q’s: how PMx and QSP coexist and integrate for MIDD

Daniela Conrado - Regeneron

11:00 AM

12:30 PM

Towards global harmonization – a new international council for guideline of model-informed drug development (MIDD)

Chair: Hao Zhu - FDA
Panel Moderator: Erin Green - Pfizer

FDA Perspectives

Million Tegenge - FDA

Health Canada Perspectives

Sarem Sarem - Health Canada 

BIO and Industry perspectives

Mark Peterson - Vertex Pharmaceuticals

PhRMA and Industry perspectives

Jenny Chien - Eli Lilly

12:00 PM

1:30 PM

Exhibits/Posters

12:00 PM

1:30 PM

Lunch

12:00 PM

1:30 PM

SIG Lunch – Clin PMx

12:00 PM

1:30 PM

SIG Lunch - MCS

12:30 PM

2:00 PM

JPKPD Meeting (by invitation only)

1:30 PM

3:00 PM

May the odds be ever in your favor: Innovative Approaches to improve Go/No-Go (GNG) decision making in Oncology

Chairs: Madhav Channavazzala - Vantage Research Inc & Tarek Leil – Daiishi Sankyo

May the odds be ever in your favor: Less so without dose finding

Kapil Mayawala - Generate Biomedicines

Leveraging historic data for generating a rigorous Synthetic Control Arm that accounts for patient covariates

Shu-wen Teng - Cstone Pharmaceuticals

Limitations of RECIST-based decision-making in Early Oncology

Brian Topp - Merck & Co

Improving the odds of selecting the winners by choosing the right outcome

Kristian Thorlund - McMaster University

1:30 PM

3:00 PM

Ocular Drug Development: How MIDD Can Brighten Our Vision

Chairs: Devineni Damayanthi - Janssen & Fernando Olinto Carreno - GSK

Current status of MIDD in ocular drug development 

Eleni Karatza - Janssen

Translational consideration and first in human dose finding in retina gene therapy

Hardik Mody - Genentech

Physiologically-based PK/PD investigation to support the development of ocular gene therapies

Carter Cao - UNC at Chapel Hill

Regulatory Experiences and Considerations for Model-Informed Approaches in Ocular Drug Development

Ping Ji - FDA

1:30 PM

3:00 PM

Latest Innovations in Model-Informed Precision Dosing Around the World

Chairs:Amparo de la Peña - Simulation Plus, Cognigen Division & Ana Ruiz - Gilead Sciences

Panelist: Ron Keizer - InsightRX

Implementation of model-informed precision dosing into routine practice

Sophie Stocker - University of Sidney

Model-informed precision dosing of anti-infectives: challenges and potential solutions

Sebastien Wicha - University of Hamburg

Model-informed precision dosing and clearance monitoring of monoclonal antibodies in patients with chronic immune-mediated inflammatory diseases.

Erwin Dreesen - KU Leuven

Model-informed precision dosing and clearance monitoring of monoclonal antibodies in patients with chronic immune-mediated inflammatory diseases

Manuel Ibarra - Universidad de la República de Uruguay

2:00 PM

5:00 PM

Trainee Workshop: Transitioning from Us to Them: A Soft Skills Workshop for Successfully Navigating Diverse Teams

Vincent Lowe & Jessica Barry, ISoP Trainee Community Hosts

3:15 PM

3:45 PM

Closing ACoP14

Sihem Bihorel - Merck & Co

4:30 PM

6:00 PM

ACoP 14 Meets ACoP 15 (by invitation only)

Thursday, November 9, 2023

Start

End

Event

Speakers

7:00 AM

8:00 AM

Coffee Service for tutorial attendees

9:00 AM

12:00 PM

Tutorial - The Art of Writing Beautiful Code

Instructors: Pete Bonate - Astellas & Andreas Krause - Idorsia Pharmaceuticals

10:00 AM

5:00 PM

Post ACoP14 Satellite Meeting focused on Oncology

12:00 PM

1:00 PM

Lunch for Oncology Workshop Attendees

12:00 PM

1:00 PM

Registration & Lunch for Post ACoP14 Workshops Attendees

1:00 PM

5:00 PM

Post Workshop (1 1/2 day) - PBPK-PD/QSP modeling with the OSPSuite (PK-Sim®, MoBi®) 

Pharmetheus

1:00 PM

5:00 PM

Post Workshop (1 1/2 day) - Pharmacometrics modeling & simulations using MonolixSuite: from introductory to advanced concepts and applications."

Lixoft/Simulations Plus

1:00 PM

5:00 PM

Post Workshop (1 1/2 day) - Advanced Clinical Trial Simulations to Support MIDD

Pumas AI

3:00 PM

3:30 PM

Coffee Break for post ACoP14 Workshop Attendees

Friday, November 10, 2023

Start

End

Event

Speakers

7:00 AM

8:00 AM

Coffee Service for Post ACoP14 Workshop Attendees

 

8:00 AM

5:00 PM

Post Workshop (1 1/2 day) -PBPK-PD/QSP modeling with the OSPSuite (PK-Sim®, MoBi®) 

Pharmetheus

8:00 AM

5:00 PM

Post Workshop (1 1/2 day) -Pharmacometrics modeling & simulations using MonolixSuite: from introductory to advanced concepts and applications."

Lixoft/Simulations Plus

8:00 AM

5:00 PM

Post Workshop (1 1/2 day) -Advanced Clinical Trial Simulations to Support MIDD

Pumas AI

12:00 PM

1:00 PM

Lunch for post ACoP14 Workshops Attendees

3:00 PM

3:30 PM

Coffee Break for Workshop Attendees

 


 

Top